180 related articles for article (PubMed ID: 11113777)
1. Breast cancer risk reduction: what do we know and where should we go?
Prout MN
Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
[TBL] [Abstract][Full Text] [Related]
2. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
3. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
5. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
Jubelirer SJ; Crowell EB
W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
[TBL] [Abstract][Full Text] [Related]
6. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
7. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
8. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
10. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
Crowell EB; Jubelirer SJ
W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
[TBL] [Abstract][Full Text] [Related]
12. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2013 Nov; 159(10):698-708. PubMed ID: 24061412
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention in postmenopausal women.
Rastogi P
Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
[TBL] [Abstract][Full Text] [Related]
14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
15. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
Powles TJ
Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
[TBL] [Abstract][Full Text] [Related]
16. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
Rollins G
Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
[No Abstract] [Full Text] [Related]
18. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
19. New approaches to the endocrine prevention and treatment of breast cancer.
Howell A; Howell SJ; Evans DG
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S39-44. PubMed ID: 12819938
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
